文献速递免疫规划传染病防控与疫情报告

儿童肺炎球菌结合疫苗对日本成人肺炎球菌肺炎的长期影响:2011至2020年两项多中心观察性研究

Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
PubMed 文献 · Vaccine · 2022-08-10

该研究通过2011-2014年和2016-2020年两项多中心观察性研究,评估日本儿童引入肺炎球菌结合疫苗(PCV)后成人肺炎球菌肺炎血清型变化。共纳入650例成人患者,PCV13血清型占比从2011-2014年的52.7%降至2016-2017年的30.4%(p<0.001),但2018-2020年PCV13、PCV15和PCV20血清型仍分别占38.5%、43.3%和59.6%。

要点

  • 儿童PCV13引入后,成人肺炎球菌肺炎中PCV13血清型占比从52.7%降至30.4%(p<0.001)。
  • 2018-2020年PCV13、PCV15和PCV20血清型分别占38.5%、43.3%和59.6%。
  • ≥65岁患者PCV13血清型下降幅度(-23.5%,p<0.001)大于<65岁患者(-12.3%,p=0.104)。

核心结论

  • 日本儿童PCV纳入国家免疫规划后,成人肺炎球菌肺炎中PCV13血清型占比下降,可能源于儿童PCV的间接效应。
  • 日本成人使用新型PCV可能预防更多肺炎球菌肺炎病例,老年人肺炎球菌疫苗接种策略有待讨论。

研究设计与样本

  • 两项多中心观察性研究,评估2011-2014年和2016-2020年日本成人肺炎球菌肺炎患者分离株的血清型。
  • 2016-2020年研究期分为2016-2017年和2018-2020年两个时段,以评估儿童PCV引入后的变化。
  • 采用Quellung反应确定血清型,共纳入650例患者:2011-2014年224例,2016-2017年322例,2018-2020年104例。

主要发现

  • 患者中位年龄73岁;男性占59.7%(388/650);有合并症者占86.9%(565/650);养老院居民占10.2%(66/650)。
  • PCV13血清型占比从2011-2014年的52.7%降至2016-2017年的30.4%(p<0.001)。
  • 2018-2020年PCV13、PCV15和PCV20血清型分别占总肺炎球菌肺炎的38.5%、43.3%和59.6%。
  • 2011-2014年至2016-2020年,≥65岁患者PCV13血清型下降23.5%(p<0.001),<65岁患者下降12.3%(p=0.104)。
  • PPSV23非PCV13血清型占比随时间无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric pneumococcal conjugate vaccines (PCVs) introduction has directly and indirectly reduced pneumococcal pneumonia and invasive disease caused by PCV-covered serotypes among children and adults globally. In Japan, both PCV7 and PCV13 were introduced into the national immunization program (NIP) for children in 2013. However, the long-term impact of PCV use in children on adult pneumococcal pneumonia in Japan remains unclear. METHODS: We assessed serotypes isolated from adult pneumococcal pneumonia patients (in- and outpatients) in two multicenter observational studies in Japan: 2011-2014 and 2016-2020. The latter study period was divided into two periods to evaluate changes after PCV introduction in children. The Quellung reaction was used to determine serotypes. We evaluated trends of individual and vaccine-covered serotypes over three periods and assessed the difference in changes by patient group before and after the introduction of pediatric PCVs. RESULTS: A total of 650 patients were enrolled: 224, 322, and 104 in 2011-2014, 2016-2017, and 2018-2020, respectively. The median age was 73 years; 59.7% (388/650) were male; 86.9% (565/650) had comorbidities; and 10.2% (66/650) were nursing-home residents. The proportion of PCV13 serotypes decreased from 52.7% in 2011-2014 to 30.4% in 2016-2017 (p <0.001) after PCV13 introduction for children. However, PCV13, PCV15, and PCV20 serotypes still accounted for 38.5, 43.3, and 59.6% of total pneumococcal pneumonia in 2018-2020, respectively. Decline of PCV13 serotypes was more marked in patients aged ≥65 (-23.5%; p <0.001) than those aged <65 (-12.3%; p = 0.104) from 2011-2014 to 2016-2020. The proportion of PPSV23 non-PCV13 serotypes didn't change over time. CONCLUSIONS: The proportion of adult pneumococcal pneumonia caused by PCV13 serotypes in Japan declined after pediatric PCVs introduction into NIP, possibly due to indirect effects of pediatric PCVs. However, use of new PCVs in Japanese adults may potentially prevent additional pneumococcal pneumonia cases. Now, pneumococcal vaccination strategy for older adults requires discussion.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Maeda H, Gopal Dhoubhadel B, Sando E, et al. Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020. Vaccine. 2022. PMID: 35963821. doi:10.1016/j.vaccine.2022.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。